Clearmind Medicine

Treatments for Binge Behavior and Mental Health

Health Tech & Life Sciences
Public on CSE on Jun 2022
Public on NASDAQ on Nov 2022

Company Overview

Snapshot

Founded in January 2021, Clearmind Medicine operates with 1–10 employees and has raised $16.21 million across six funding rounds. In November 2022, the company uplisted to the NASDAQ Capital Market, following its public listing on the CSE in June 2022.

Business overview

Clearmind Medicine is a Health Tech & Life Sciences company focused on developing treatments for binge behavior and mental health conditions, including alcohol use disorder, binge eating, and depression. Its core product, MEAI, is designed to provide a euphoric, alcohol-like experience while reducing the desire for alcohol consumption, aiming to support individuals struggling with moderation. The company operates in the Pharma & Medical Biotechnology sector, specifically within Drugs Discovery & Development, targeting healthcare laboratories with its novel molecules.

Strategic signal

In September 2024, Clearmind Medicine announced the publication of an international patent application for an innovative MDMA-based combination treatment. This development, alongside a similar patent for an Ibogaine combination therapy, signals the company's strategic expansion into novel psychedelic-derived therapies, potentially broadening its pipeline beyond MEAI and demonstrating a commitment to intellectual property in the rapidly evolving mental health treatment landscape.

Company Intelligence Q&A

What was a significant recent development regarding Clearmind Medicine's intellectual property?
In September 2024, Clearmind Medicine announced the publication of an international patent application for an innovative MDMA-based combination treatment, indicating progress in its psychedelic-derived therapies.
What was the outcome of Clearmind Medicine's public offering in September 2023?
In September 2023, Clearmind Medicine closed a US$2.25 million public offering, with Aegis Capital Corp. acting as the exclusive placement agent.
What progress has Clearmind Medicine made in its clinical trials for Alcohol Use Disorder?
In November 2025, Clearmind Medicine announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder, and its Data and Safety Monitoring Board unanimously approved the continuation of the trial.
What strategic partnership did Clearmind Medicine announce in September 2023?
In September 2023, Clearmind Medicine announced a clinical research collaboration with Johns Hopkins University to evaluate CMND-100 in patients with Alcohol Use Disorder.
What was a key leadership appointment at Clearmind Medicine in October 2025?
In October 2025, Clearmind Medicine appointed Mary-Elizabeth Gifford as Chief of Global Impact to advance US partnerships and governmental engagement.

External links